| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer
1 company
Robert Glanzman last filed a Form 4 in May 2022, as Chief Medical Officer at CLNN. Robert Glanzman's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 10,564 shares of CLNN. The CLNN filings lean toward selling, a net 4,717 shares.
Robert Glanzman has 5 Form 4 filings on record from April 2021 to May 2022, all as Chief Medical Officer at Clene (CLNN), 2021–2022.
The 5 reported transactions were 3 option or other derivative awards, 1 open-market sale and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $10K.
The only open-market sale was 4,717 shares of CLNN at an average $2.03 on May 16, 2022, about $10K. Twelve months later CLNN was down 58%.
Shares as reported in the last Form 4 for each company; the most recent is from May 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 16, 2022 | CLNN Clene Inc. | Chief Medical Officer | Sell | 4,717 | $2.03 | $9,575.51 | -30.9% | +70.6% | -57.9% |